<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320697">
  <stage>Registered</stage>
  <submitdate>12/10/2009</submitdate>
  <approvaldate>19/10/2009</approvaldate>
  <actrnumber>ACTRN12609000904279</actrnumber>
  <trial_identification>
    <studytitle>Study of  changes in cancer tissue induced by treatment with bevacizumab in metastatic breast cancer</studytitle>
    <scientifictitle>Study of molecular changes induced by treatment with bevacizumab in metastatic breast cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>metastatic breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Biopsy of tissue from recurrent or metastatic breast cancer (only skin, lymph node, breast tumor biopsies allowed) on day 0, administration of bevacizumab 10mg/kg on day 1 (intravenously infused over 90 min) and re-biopsy on day 14.</interventions>
    <comparator>no control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>changes in the expression of certain genes induced by a single dose of bevacizumab. Changes in gene expression will be assessed with the use of superarray technology (commercially available through Bioscience Corporation). Genes of interest are the Notch pathway and angiogenesis pathway (sets of genes available commercially through Bioscience Corporation)</outcome>
      <timepoint>14 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>changes of plasma levels of certain angiogenic markers vascular endothelial growth factor (VEGF),  soluble vascular endothelial growth factor receptor (sVEGFR), angiopoietins, basic fibroblast growth factor (bFGF), Tie-1/2, angiostatin, circulating endothelial cells (CEC)</outcome>
      <timepoint>14 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>histologically proven metastatic breast cancer, locally accessible disease (breast tumor, skin mets, lymph node mets), Performance status (PS) 0-1, normal liver and kidney function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>history of thrombotic disease, uncontrolled brain metastases, pregnancy, lactation, prior bevacizumab exposure, recent surgery (within 4 weeks), active bleeding, active infection, unhealed wound, use of anticoagulants in therapeutic doses</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Detailed discussion with all eligible patients</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>19/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Greece</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Georgios Kesisis</primarysponsorname>
    <primarysponsoraddress>44 Gennimata str
55134-Kalamaria
Thessaloniki
Greece</primarysponsoraddress>
    <primarysponsorcountry>Greece</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Hellenic Association for Cancer Research</fundingname>
      <fundingaddress>2 Al Simeonidi str
1st Floor 
Applied Molecular Oncology Laboratory
54007
Thessaloniki 
Greece</fundingaddress>
      <fundingcountry>Greece</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Konstantinos Papazisis</sponsorname>
      <sponsoraddress>2 Al Simeonidi str
7th Floor
3rd department of Medical Oncology
54007
Thessaloniki</sponsoraddress>
      <sponsorcountry>Greece</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will try to identify molecular changes in tumor tissue induced by treatment with bevacizumab</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Theagenion Ethics Committee</ethicname>
      <ethicaddress>2 Al Simeonidi str,
54007
Thessaloniki</ethicaddress>
      <ethicapprovaldate>6/02/2009</ethicapprovaldate>
      <hrec>1421-10/02/2009</hrec>
      <ethicsubmitdate />
      <ethiccountry>Greece</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Georgios Kesisis</name>
      <address>44 Gennimata str
55134, Kalamaria
Thessaloniki</address>
      <phone>+306974316307</phone>
      <fax />
      <email>gkesisis@gmail.com</email>
      <country>Greece</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georgios Kesisis</name>
      <address>44 Gennimata str
55134, Kalamaria
Thessaloniki</address>
      <phone>+306974316307</phone>
      <fax />
      <email>gkesisis@gmail.com</email>
      <country>Greece</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georgios Kesisis</name>
      <address>44 Gennimata str
55134, Kalamaria
Thessaloniki</address>
      <phone>+306974316307</phone>
      <fax>+302310240706</fax>
      <email>gkesisis@gmail.com</email>
      <country>Greece</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>